Abstract

Psoriasis and psoriatic arthritis are common diseases associated with considerable morbidity and disability. Their pathophysiology comprises similar processes leading to inflammation of skin, entheses, and joints. Although traditional systemic agents can be effective, their use may be limited by lack of efficacy and concerns regarding adverse effects. The objective of this study was to assess the efficacy and safety of adalimumab, a fully human antitumor necrosis factor (anti-TNF) monoclonal antibody, over 16 weeks. The present authors report their personal experience in 15 patients with severe plaque psoriasis and psoriatic arthritis, refractory to other treatments, in which a decisive regression of joint/skin involvement was obtained. Psoriasis and psoriatic arthritis are chronic inflammatory disorders resulting from a combination of genetic and environmental factors.
Lingua originaleEnglish
pagine (da-a)S15-S20
Numero di pagine6
RivistaDermatologic Therapy
Volume21
Stato di pubblicazionePublished - 2008

Fingerprint

Psoriatic Arthritis
Psoriasis
Joints
Skin
Necrosis
Therapeutics
Monoclonal Antibodies
Inflammation
Morbidity
Safety
Adalimumab

All Science Journal Classification (ASJC) codes

  • Dermatology

Cita questo

@article{e26eeab382f84c698bb69938464cf876,
title = "Adalimumab For Treatment Of Moderate–Severe Psoriasis And Psoriatic Arthritis",
abstract = "Psoriasis and psoriatic arthritis are common diseases associated with considerable morbidity and disability. Their pathophysiology comprises similar processes leading to inflammation of skin, entheses, and joints. Although traditional systemic agents can be effective, their use may be limited by lack of efficacy and concerns regarding adverse effects. The objective of this study was to assess the efficacy and safety of adalimumab, a fully human antitumor necrosis factor (anti-TNF) monoclonal antibody, over 16 weeks. The present authors report their personal experience in 15 patients with severe plaque psoriasis and psoriatic arthritis, refractory to other treatments, in which a decisive regression of joint/skin involvement was obtained. Psoriasis and psoriatic arthritis are chronic inflammatory disorders resulting from a combination of genetic and environmental factors.",
author = "Mario Arico' and Giuseppe Pistone and Bongiorno, {Maria Rita} and Spyridoula Doukaki",
year = "2008",
language = "English",
volume = "21",
pages = "S15--S20",
journal = "Dermatologic Therapy",
issn = "1396-0296",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Adalimumab For Treatment Of Moderate–Severe Psoriasis And Psoriatic Arthritis

AU - Arico', Mario

AU - Pistone, Giuseppe

AU - Bongiorno, Maria Rita

AU - Doukaki, Spyridoula

PY - 2008

Y1 - 2008

N2 - Psoriasis and psoriatic arthritis are common diseases associated with considerable morbidity and disability. Their pathophysiology comprises similar processes leading to inflammation of skin, entheses, and joints. Although traditional systemic agents can be effective, their use may be limited by lack of efficacy and concerns regarding adverse effects. The objective of this study was to assess the efficacy and safety of adalimumab, a fully human antitumor necrosis factor (anti-TNF) monoclonal antibody, over 16 weeks. The present authors report their personal experience in 15 patients with severe plaque psoriasis and psoriatic arthritis, refractory to other treatments, in which a decisive regression of joint/skin involvement was obtained. Psoriasis and psoriatic arthritis are chronic inflammatory disorders resulting from a combination of genetic and environmental factors.

AB - Psoriasis and psoriatic arthritis are common diseases associated with considerable morbidity and disability. Their pathophysiology comprises similar processes leading to inflammation of skin, entheses, and joints. Although traditional systemic agents can be effective, their use may be limited by lack of efficacy and concerns regarding adverse effects. The objective of this study was to assess the efficacy and safety of adalimumab, a fully human antitumor necrosis factor (anti-TNF) monoclonal antibody, over 16 weeks. The present authors report their personal experience in 15 patients with severe plaque psoriasis and psoriatic arthritis, refractory to other treatments, in which a decisive regression of joint/skin involvement was obtained. Psoriasis and psoriatic arthritis are chronic inflammatory disorders resulting from a combination of genetic and environmental factors.

UR - http://hdl.handle.net/10447/36274

M3 - Article

VL - 21

SP - S15-S20

JO - Dermatologic Therapy

JF - Dermatologic Therapy

SN - 1396-0296

ER -